Literature DB >> 33634988

Activation of CXCL16/CXCR6 axis aggravates cardiac ischemia/reperfusion injury by recruiting the IL-17a-producing CD1d+ T cells.

Shijun Wang1,2, Leilei Ma1, Ji'e Yang1, Zhen Dong1, Jian Wu1,2, Xiancheng Lu3, Jiahong Wang4, Fangjie Dai1, Guowei Tu1, Lei Xu1, Gang Zhao1, Feng Zhang1, Yunzeng Zou1,2, Junbo Ge1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33634988      PMCID： PMC7839957          DOI： 10.1002/ctm2.301

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


× No keyword cloud information.
  10 in total

Review 1.  The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Authors:  Sayam Dubash; Charlie Bridgewood; Dennis McGonagle; Helena Marzo-Ortega
Journal:  Expert Rev Clin Immunol       Date:  2019-01-08       Impact factor: 4.473

2.  C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes.

Authors:  Thomas Andersen; Thor Ueland; Tatevik Ghukasyan Lakic; Axel Åkerblom; Maria Bertilsson; Pål Aukrust; Annika E Michelsen; Stefan K James; Richard C Becker; Robert F Storey; Lars Wallentin; Agneta Siegbahn; Frederic Kontny
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-26       Impact factor: 8.311

3.  Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells.

Authors:  Elitza Germanov; Linnea Veinotte; Robyn Cullen; Erin Chamberlain; Eugene C Butcher; Brent Johnston
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

4.  Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration.

Authors:  Yu-Hua Liao; Ni Xia; Su-Feng Zhou; Ting-Ting Tang; Xin-Xin Yan; Bing-Jie Lv; Shao-Fang Nie; Jing Wang; Yoichiro Iwakura; Hong Xiao; Jing Yuan; Harish Jevallee; Fen Wei; Guo-Ping Shi; Xiang Cheng
Journal:  J Am Coll Cardiol       Date:  2012-01-24       Impact factor: 24.094

5.  IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury.

Authors:  Mayya Geha; Maria G Tsokos; Robin E Bosse; Tatyana Sannikova; Yoichiro Iwakura; Jurandir J Dalle Lucca; Rene De Waal Malefyt; George C Tsokos
Journal:  J Immunol       Date:  2017-09-06       Impact factor: 5.422

6.  The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling.

Authors:  Bysani Chandrasekar; Srinivas Mummidi; Anthony J Valente; Devang N Patel; Steven R Bailey; Gregory L Freeman; Masahiko Hatano; Takeshi Tokuhisa; Liselotte E Jensen
Journal:  J Biol Chem       Date:  2005-05-11       Impact factor: 5.157

7.  CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas.

Authors:  Matthew J Butcher; Chih-I Wu; Tayab Waseem; Elena V Galkina
Journal:  Int Immunol       Date:  2015-11-27       Impact factor: 4.823

8.  CXCL16 silencing alleviates hepatic ischemia reperfusion injury during liver transplantation by inhibiting p38 phosphorylation.

Authors:  Yijie Zhang; Qi Pan; Yongfeng Liu
Journal:  Pathol Res Pract       Date:  2020-03-02       Impact factor: 3.250

9.  Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.

Authors:  Robyn Cullen; Elitza Germanov; Takeshi Shimaoka; Brent Johnston
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

10.  Therapeutic potential of targeting IL-17 and IL-23 in sepsis.

Authors:  Markus Bosmann; Peter A Ward
Journal:  Clin Transl Med       Date:  2012-04-27
  10 in total
  1 in total

1.  CXCR6 Mediates Pressure Overload-Induced Aortic Stiffness by Increasing Macrophage Recruitment and Reducing Exosome-miRNA29b.

Authors:  Shijun Wang; Jian Wu; Xuan Li; Rubin Tan; Liming Chen; Lifan Yang; Fangjie Dai; Leilei Ma; Lei Xu; Zhen Wang; Gang Zhao; Junbo Ge; Yunzeng Zou
Journal:  J Cardiovasc Transl Res       Date:  2022-08-26       Impact factor: 3.216
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.